GLP-1 Tracker: Lilly Kwikpen catapulted by medicare (W/E July 17th)

Research evidence excerpt

GLP-1 Tracker: Lilly Kwikpen catapulted by medicare (W/E July 17th)

24 July 2026

US Biopharmaceuticals

GLP-1 Tracker: Lilly Kwikpen catapulted by medicare (W/E July

17th)

Total GLP-1 scripts have rebounded as holiday-affected period moves to the rearview mirror, Courtney Breen

+1 917 344 8407 and Medicare access begins to materialize, increasing 6.6% WoW, or 167k, to 2.69M (an all-

courtney.breen@bernsteinsg.com time high). Growth was relatively broad-based across the major brands, however Zepbound

has been a beneficiary in the early data we’ve seen post-Medicare obesity access; NBRx

Woody Polglase are up ~30% on the average of the prior 4 weeks before 1-Jul. This is driven mainly by the

+1 917 344 8314

woody.polglase@bernsteinsg.com Kwikpen (Exhibit 1; the only Zepbound offering in the Bridge program), and whilst there are

declines in the vial presentation, this is to be expected, and still nets out positively. We can

Louisa Qiu also now see an increase in obesity TRx after Medicare access became available (Exhibit

+1 917 344 8495 3). Foundayo scripts increased by 2,458 WoW, or 10.1%, to 26,761 in week 15 of launch,

louisa.qiu@bernsteinsg.com

extending last week’s uptick. Wegovy Pill also accelerated, with scripts increasing by 22.2k

WoW, or 15.1%, to 170k in week 28.Specialist Sales

Christian Moore Total scripts: Total weekly scripts were 2.69M, up 6.63% WoW, or 167k in absolute terms.

+1 917 344 8555 Semaglutide plus tirzepatide volumes increased 1.8% on a rolling four-week sequential

christian.moore@bernsteinsg.com

basis, while rolling four-week YoY growth was stable at 33.3%. The company market-

share split on a TRx basis remained broadly stable at 61.0% Lilly versus 39.0% Novo,

compared with 61.1% and 38.9%, respectively, last week. Product-level share was 27.7%